| Code | CSB-RA004954MB2HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to BR108, targeting CD70 (also known as CD27 ligand), a type II transmembrane glycoprotein belonging to the tumor necrosis factor superfamily. CD70 expression is tightly regulated in normal tissues, appearing transiently on activated T cells, B cells, and dendritic cells during immune responses. However, aberrant constitutive CD70 expression has been documented in various hematological malignancies including non-Hodgkin lymphoma, multiple myeloma, and Waldenström's macroglobulinemia, as well as solid tumors such as renal cell carcinoma and glioblastoma. The CD70-CD27 interaction plays crucial roles in T cell activation, B cell differentiation, and immune memory formation, making dysregulated CD70 expression a significant contributor to tumor immune evasion and cancer progression.
BR108 is an established research antibody used extensively in oncology and immunology studies to investigate CD70-mediated signaling pathways and immune regulation. This biosimilar provides researchers with a reliable tool for studying CD70 biology, tumor immunology, and potential therapeutic targeting strategies in CD70-positive malignancies.
There are currently no reviews for this product.